Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.84 |
| ▸ | CTSK | P43235 | 16/20 | 0.84 |
| ▸ | CTSB | P07858 | 4/20 | 0.74 |
| ▸ | CTSL | P07711 | 2/20 | 0.74 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704295 | 1.00 | CTSS (0.84) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6790738 | 0.95 | CTSS (0.83) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6019878 | 0.95 | CTSS (0.83) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3696863 | 0.89 | CTSL (0.68) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3696864 | 0.89 | CTSL (0.68) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6021008 | 0.89 | CTSS (0.81) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6019886 | 0.87 | CTSS (0.83) | CTSSCTSKCTSBCTSL | |
| SCHEMBL8739537 | 0.86 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6020639 | 0.85 | CTSS (1.00) | CTSSCTSKCTSBCTSL | |
| SCHEMBL14599153 | 0.85 | CTSS (1.00) | CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-0660840-B1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996026729-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES AS ECE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-09-06 | — | — | WO | disclosed |
| US-5550119-A | ENDOTHELIN-CONVERTING ENZYM INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0660840-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES. | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994005677-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-03-17 | — | — | WO | disclosed |
| US-5273990-A | 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CTSS 357/4885CTSK 252/4885CTSB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.